Author

M. Weir

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Results from the Phase 2 Explore-CKD Trial of lorundrostat, a novel aldosterone synthase inhibitor, in participants with uncontrolled hypertension, chronic kidney disease, and albuminuria.

INTRODUCTION Dysregulated aldosterone plays an important role in the pathogenesis of hypertension (HTN) and chronic kidney disease (CKD). Lorundrostat, a highly selective aldosterone synthase inhibitor, has demonstrated efficacy and safety for uncontrolled HTN (uHTN) and treatment-resistant HTN in multiple well-control...

M. Weir, S. Bhaduri, Keung Lee et al. · Kidney International · 0 citations

Review Oct 2026

Resistant Hypertension: State of the Art Review.

Resistant hypertension, defined as blood pressure above target despite treatment with at least three antihypertensive agents (including a diuretic) or controlled blood pressure requiring four or more medications, affects over 140 million individuals globally and confers increased risks of heart failure, stroke, and chr...

M. S. Khan, Muhammad Sameer Arshad, Michael E. Hall et al. · American Society of Nephrolo... · 0 citations

Review Open access Aug 2026

Eplerenone Revisited: A Balanced Reappraisal of Its Role in Hypertension, Heart Failure, and Cardiorenal Disease.

Mineralocorticoid receptor activation contributes to cardiovascular and kidney injury through inflammation, fibrosis, oxidative stress, endothelial dysfunction, and adverse tissue remodeling. Eplerenone, a selective steroidal mineralocorticoid receptor antagonist developed to minimize the endocrine adverse effects asso...

V. Bogin, M. Weir · Journal of Cardiovascular Ph... · 0 citations